Company intelligence / Profile preview

Ophidian Pharmaceuticals

Madison or Milwaukee area* (*exact city not specified in available records), Wisconsin, United Statesophid.org ↗

Ownership: Private
Employees: ~55
Development stage: Other

Overview

Ophidian Pharmaceuticals developed proprietary technology for producing and purifying toxin antibodies from polyclonal sources, especially using egg yolks instead of horse serum. Their main focus was on anti-toxin therapies for snake bites and other envenomations, with additional research into preventive agents for sepsis and treatments for opportunistic infections in AIDS. The company partnered with Wyeth-Ayerst to develop improved anti-snake venom products but ultimately faced financial difficulties and ceased operations around 2000[5][8].

Therapeutic areas: OtherImmunologyInfectious Diseases
Modalities: AntibodyProtein
Industry: Biotech

Partnerships

Wyeth-Ayerst Laboratories

Beyond the preview

Go deeper on Ophidian Pharmaceuticals.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Ophidian Pharmaceuticals.

Explore the full profile